tv.qiagenbioinformatics.com

QIAGEN and NVIDIA collaboration to advance AI driven drug discovery

Fri, 29 May 2026 13:24:12 GMT

NVIDIA and QIAGEN are collaborating to bring trustworthy, contextual AI to drug discovery. By integrating NVIDIA's accelerated computing and the BioNeMo platform with QIAGEN Digital Insights' manually curated biomedical knowledge graphs, cited in over 70,000 peer-reviewed publications; the collaboration aims to transform how disease mechanisms, therapeutic targets, and biomarkers are identified. Using a graph-based AI approach built on G-Retriever, the solution delivers 5–10x better performance than standard RAG pipelines, giving researchers answers they can trust, defend, and act on. In this conversation from Bio-IT World 2026, NVIDIA's Ben Busby and QIAGEN's Venkatesh Moktali discuss what each side brings, why knowledge graphs are a must-have for pharma AI, and what's coming next — including initial pilots with select pharma and biotech partners ahead of broader availability.

Hybrid Variant Interpretation: Combining AI + Expert Curation to Streamline...

Wed, 11 Mar 2026 08:24:50 GMT

As hereditary NGS testing grows more complex, clinical labs must interpret variants with greater speed and accuracy. This webinar introduces Franklin by QIAGEN, now integrated with HGMD Professional, combining AI-powered workflows and automated ACMG annotation with the leading expert-curated germline database. Together, they enable faster, evidence-backed interpretation, reduce manual review, and boost reporting confidence by minimizing missed clinically relevant findings.

In this webinar, you’ll see how Franklin + HGMD accelerates variant matching, streamlines VUS assessment, supports long-read sequencing, and delivers instant access to curated clinical and functional evidence—all through a unified interpretation workflow.

Key highlights include:

Integrated ACMG-based annotation + automatic literature curation for evidence-backed interpretation
Instant variant matching to quickly identify known, reported, or novel variant
Faster VUS resolution with direct access to relevant publications and functional data
Minimal manual literature search with direct links to HGMD Professional in-platform
Long-read sequencing support for interpreting complex alleles and structural variants

Cross-species comparison and validation for drug discovery and biomarker...

Wed, 27 Sep 2023 14:11:02 GMT

Some human studies may be unfeasible or unethical, making cross-species research critical for drug discovery and biomarker validation. Cross-species research is a crucial method to collect data to examine potential toxicity for a candidate drug, determine the efficacious doses that may be suitable for humans, identify potential biomarkers for a disease of interest or a therapeutic response and understand the mechanisms of disease or treatment. While animal models and humans have similar anatomy and physiology, the subtle differences among organisms in the animal kingdom need to be considered and data collected must be interpreted using a meaningful method.

Using QIAGEN IPA, you can perform comparative analyses across various animal models, even combining different time points, treatments, tissues and cell types with data generated from a wide variety of ‘omics technologies (RNA-seq, scRNA-seq, proteomics, metabolomics, etc.). In this training, you will learn how to:
1. Generate activity heatmaps and expression charts comparing different pathways and regulatory networks across different species
2. Use Activity Plot, Pattern Search and Analysis Match to compare your own data against thousands of public data pre-curated and pre-analyzed representing an array of disease states, conditions and other biological conditions
3. Create expression and correlation plots using pre-curated and pre-analyzed public data to validate and confirm findings derived from a comparison analysis

Expanding Germline and Somatic Variant Knowledge and Interpretation

Thu, 08 Sep 2022 19:37:27 GMT

In this 60-minute webinar, learn how the online resources of the Human Gene Mutation Database (HGMD) Professional and the Human Somatic Mutation Database (HSMD) can improve the quality, and decrease the time needed for variant classification and interpretation.

Users will discover how to use both these expert-curated resources for the annotation and understanding of next-generation sequencing data in routine clinical and translational research.

Knowledge graphs and more: Analytics-driven drug discovery using advanced...

Tue, 19 Jul 2022 16:01:43 GMT

High-quality biomedical relationships knowledge is the cornerstone of modern and innovative data- and analytics-driven drug discovery. Yet this knowledge is locked in thousands of publications and dozens of databases. This webinar will show you how to unlock this knowledge and use it to strengthen your efforts in data science-driven drug discovery.

In this webinar, you'll learn about:

High-quality biomedical relationships knowledge: What it is and how to access it
Knowledge graphs and knowledge graph analysis
Artificial intelligence (AI)-driven target identification and drug repositioning using knowledge graphs and biomedical relationships
Disease subtyping and biomarker identification based on functional features
Target, disease and drug intelligence portals: Application development and data integration leveraging biomedical relationships

Don't miss this opportunity to discover how to give your drug discovery programs a data science-driven advantage by leveraging high-quality biomedical relationships knowledge.

50 to 500 genes: Scale-up to comprehensive genomic profiling

Wed, 13 Jul 2022 08:28:03 GMT

In this webinar, we present a workflow-agnostic, informatics software solution that enables clinical diagnostic labs to scale to CGP while reducing cost, time, and labor. Already used and trusted to interpret over 3 million patient cases worldwide, this software solution leverages the world’s largest and fastest-growing knowledge base to simplify and accelerate variant interpretation and build custom, patient-specific reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials.

In this webinar, you will:

Learn how to overcome unique challenges of CGP, including identifying incidental germline findings and interpreting co-occurring variants.
See why 90,000 users trust QIAGEN Digital Insights for knowledge curation—how we have built the most trusted, fastest growing knowledge base and why our curation process is unrivalled in the industry.
Receive step-by-step guide of how to perform CGP and go from VCF to final report with greater speed, precision, and confidence (all registrants can receive custom report if VCF files are provided).
Qualify for a complimentary demonstration and trial of this industry-leading software to see how your lab can scale to CGP while reducing costs, time, and labor.